ArticleDiabetes2017
Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction.
Article in Diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2018Trial
- GLP-1 and the cardiovascular system.The Journal of clinical investigation · 2026Review
- Impact of obesity on infarct size, circulating biomarkers, mitochondrial function and mortality in a Göttingen minipig myocardial infarct model.Lab animal · 2025Article
- Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.Cardiovascular diabetology · 2024Review
- GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.The Journal of endocrinology · 2024Review
- The pig as an optimal animal model for cardiovascular research.Lab animal · 2024Review
- Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.Nature reviews. Cardiology · 2023Review
- Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.Obesity facts · 2023Review
- Chronic high-rate pacing induces heart failure with preserved ejection fraction-like phenotype in Ossabaw swine.Basic research in cardiology · 2022Article
- Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.Diabetes · 2022Review
- Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.Journal of diabetes research · 2022Review
- GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.International journal of biological sciences · 2021Review
- Liraglutide restores late cardioprotective effects of remote preconditioning in diabetic rats via activation of hydrogen sulfide and nuclear factor erythroid 2-related factor 2 signaling pathway.Acta cirurgica brasileira · 2021Article
- Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients.Journal of diabetes investigation · 2020Article
- Large Animal Models of Heart Failure: A Translational Bridge to Clinical Success.JACC. Basic to translational science · 2020Review
- A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent ImplantationFrontiers in pharmacology · 2020Article
- Article
- The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardiac contractile function at rest and in response to adrenergic stimulation in obese swine after myocardial infarction. Obese Ossabaw swine were subjected to gradually developing regional coronary occlusion using an ameroid occluder placed around the left anterior descending coronary artery. Animals received subcutaneous injections of saline or liraglutide (0.005-0.015 mg/kg/day) for 30 days after ameroid placement. Cardiac performance was assessed at rest and in response to sympathomimetic challenge (dobutamine 0.3-10 μg/kg/min) using a left ventricular pressure/volume catheter. Liraglutide increased diastolic relaxation (dP/dt; Tau
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.